Design and synthesis of novel peptidomimetics for cancer immunotherapy

Ceyda Köse, Esra Uysal, Büşra Yazıcı, Zeynep Tuğay, Serap İpek Dingiş Birgül, Hamdullah Yanık, Ece Tavukçuoğlu, Sevgi Gülyüz, Atilla Akdemir, Güneş Esendağlı, Özgür Yılmaz*, Onur Alptürk

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Tumor cells benefit from some certain signals, which are referred to as “immune checkpoints”, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.

Original languageEnglish
Pages (from-to)89-102
Number of pages14
JournalOrganic Communications
Volume13
Issue number3
DOIs
Publication statusPublished - 2020

Bibliographical note

Publisher Copyright:
©2020 ACG Publications. All right reserved.

Keywords

  • 2-aminobenzothiazole
  • Immunotherapy
  • PD-1
  • PD-L1
  • peptidomimetics

Fingerprint

Dive into the research topics of 'Design and synthesis of novel peptidomimetics for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this